Raffaella C.
- Country
- Italy
- Department
- N/A
Research Overview
- Evaluation of Etavopivat, a Pyruvate Kinase Activator, in a Randomized, Placebo-Controlled Study for Sickle Cell Disease in Patients Aged 12 to 65 Years
- Efficacy and Safety Evaluation of Oral Decitabine-Tetrahydrouridine in Hydroxyurea-Non-Eligible Sickle Cell Disease Patients
- Phase IV, Open-label, Multi-center Rollover Study of Crizanlizumab in Patients with Sickle Cell Disease Post-Novartis-Sponsored Study Completion
Data & Insights
Has run more than one trial at 35 of 61 partner sites.
Specializations
Hematologic Disorders
The investigator specializes in treating sickle cell disease (SCD) and its various manifestations, with particular emphasis on managing acute complications like vaso-occlusive crisis.
- Sickle Cell Disease Management
- Hemoglobin Disorders
- Thalassemia Care
Their work includes evaluation of novel therapeutic approaches for both acute and chronic manifestations of blood disorders.
Therapeutic Innovation
The investigator focuses on developing innovative treatments including oral and intravenous therapies for blood disorders, with particular attention to hemopexin-based treatments and novel pharmaceutical compounds.
- Novel Drug Development
- Treatment Optimization
- Long-term Disease Management
Their research encompasses both established and experimental therapeutic approaches for hematologic conditions.
Clinical Outcomes
The investigator's work centers on improving hemoglobin levels and reducing complications in patients with blood disorders, with specific focus on crisis prevention and management.
- Disease Progression Monitoring
- Crisis Prevention Strategies
- Quality of Life Enhancement
Their research aims to enhance treatment outcomes across different age groups, from adolescents to adults.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.